Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 31%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is a German biotechnology company with an 8% discounted cash flow-based valuation, a projected effective tax rate of 28% and a $33 billion firm value, mainly driven by its oncology pipeline, covid vaccine and its expected cash and trade receivables. Risks include potential negative data, slow market uptake and the recent spinoff of CEO Ugur Sahin and his spouse to start a new mRNA-focused biotech company, which we believe does not impact the intrinsic value of BioNTech's core operations. COVID revenues are expected to decline as the company shifts focus to its oncology pipeline, which we view as a positive for long-term growth and success.

Bears say

BioNTech is highly valued, but risks include slower than expected market uptake of its commercialized product, BioNTech might struggle to advance other programs in a timely manner such as negative data for BNT122, BNT111, BNT113, BNT116, BNT211, BNT316, BNT323, and BNT327, and partnership and/or M&A risks. Additionally, there is a possibility of long-term dilution risk.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 31% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $127.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $127.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.